T1	Participants 408 506	A prospective randomized controlled trial was conducted in patients with curative resection of HCC
T2	Participants 705 800	During a median follow up of 818 days, 21 patients received one dose and 19 received four doses
T3	Participants 1228 1307	There is no significant difference in the survival rates between the two groups
